Kala Pharmaceuticals Revenue and Competitors

Claim your profile

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Kala Pharmaceuticals's estimated annual revenue is currently $11.6M per year.(i)
  • Kala Pharmaceuticals received $110.0M in venture funding in October 2018.
  • Kala Pharmaceuticals's estimated revenue per employee is $54,299
  • Kala Pharmaceuticals's total funding is $506.4M.
  • Kala Pharmaceuticals's current valuation is $66.2M. (January 2022}

Employee Data

  • Kala Pharmaceuticals has 214 Employees.(i)
  • Kala Pharmaceuticals grew their employee count by 0% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. For more information, please visit Kala's website at www.kalarx.com.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Security,Wind Power


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Kala Pharmaceuticals News

2016-04-13 - Kala Pharmaceuticals Closes $68M Series C Financing

Kala Pharmaceuticals, Inc., a Waltham, MA-based developer of innovative ophthalmic products based on its proprietary mucus-penetrating particle (MPP) technology, closed $68m Series C financing. The round was led by Longitude Capital with participation from new investors OrbiMed, Vivo Capital an ...

2021-11-15 - Kala Pharmaceuticals Announces Time Change for Third Quarter 2021 Financial Results Conference Call

WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has changed the time of ...

2021-11-15 - Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Diseases

-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing -- -- KPI-012 demonstrated positive safety and efficacy results in PCED Phase 1b clinical trial -- -- Kala expects to init ...

24-Aug-19 - Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Kala Pharmaceuticals, Inc. (KALA), today announced that the Company granted non-statutory stock options to new employees as inducement ...

31-Aug-19 - Kala Pharmaceuticals to Present at Two Upcoming Investor Conferences in September

Kala Pharmaceuticals, Inc. (KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its ...

12-Sep-19 - Kala Pharmaceuticals, Inc. (KALA) Quickly Moves 3.46%; May Remain in Focus Today

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) is among the top stocks that may remain in focus today as the company shares are trading 3.46% ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Kala Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2012-03-15$6.2MUndisclosedLux Capital, Polaris Venture PartnersArticle
2013-03-01$11.5MACrown Venture Fund LLCArticle
2014-04-24$22.5MBYsios CapitalArticle
2016-04-14$68.0MCLongitude CapitalArticle
2018-10-03$110.0MUndisclosedAthyrium Capital ManagementArticle